CTOs on the Move

QUATRx Pharmaceuticals Company

www.quatrx.com

 
QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.quatrx.com
  • 777 E Eisenhower Pkwy
    Ann Arbor, MI USA 48108
  • Phone: 734.913.9900

Executives

Name Title Contact Details

Similar Companies

Resolve Biosciences

Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology. The platform features the company`s proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through Resolve Biosciences` commercial service laboratory. Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif.

Sentigen Biosciences

Sentigen Biosciences is a Phillipsburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Montesino Associates

Montesino Associates is a Sparta, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.

Aerin Medical

Aerin`s advanced treatment platform utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion. Treatment styluses are uniquely designed for each procedure and deliver energy to the target tissue surface without the need for incisions or tissue penetration.Proprietary algorithms ensure that targeted tissues are exposed to carefully controlled energy resulting in treatment temperatures that are below the tissue ablation range. The technology is protected by a comprehensive patent estate consisting of both method and design patents.